When Good Intentions Meet Bad Data: Why Pharma Patient Research Projects Go Off Track
Pharmaceutical companies invest billions to understand patients. Market research teams conduct thousands of surveys and collect patient-reported outcomes with the genuine intent of developing better therapies and launching products that meet real patient needs. Yet despite these investments, six out of ten pharmaceutical drug launches underperform in their first year.1 Further, over half of all […]
Why the FDA’s New Plausible Mechanism Pathway Demands a Data Revolution
FDA’s proposed Plausible Mechanism Pathway for bespoke therapies implicitly assumes a robust real‑world data (RWD) and real‑world evidence (RWE) ecosystem 1, even though the article only briefly names it in the context of postmarketing commitments. That ecosystem can be leveraged far earlier in development to de‑risk first‑in‑human interventions, enrich tiny trials, and create cumulative evidence […]
Fraud in Life Sciences Market Research: A Growing Problem with a Recently Available Solution
Fraud in Life Sciences Market Research: A Growing Problem with a Recently Available Solution Market research in life sciences increasingly relies on online surveys to gather insights on patient behaviors, treatment outcomes, and disease burden. However, a pervasive and expanding threat is fraud, where bots or individuals pose as patients with fabricated diagnoses solely to […]
